Skip to content
CancerIndex

Loading the knowledge graph…

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) — knowledge graph · CancerIndex